Solid Biosciences (SLDB) Capital Leases (2018 - 2024)

Solid Biosciences has disclosed Capital Leases across 7 years of filings, most recently posting $307000.0 for Q3 2024.

• Capital Leases for Q3 2024 came in at $307000.0, down 77.46% year-over-year; the trailing twelve-month figure through Sep 2024 was $307000.0 (down 77.46% YoY), and the FY2023 annual result was $1.2 million, down 27.54% from the prior year.
• Capital Leases came in at $307000.0 for Q3 2024 at Solid Biosciences, down from $953000.0 in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $1.7 million in Q4 2022 to a low of $231000.0 in Q1 2022.
• The 5-year median for Capital Leases is $632000.0 (2020), against an average of $818470.6.
• Across the five-year window, Capital Leases soared 590.91% in 2023 and slumped 77.46% in 2024, its largest moves.
• Solid Biosciences' Capital Leases stood at $525000.0 in 2020, then slumped by 44.19% to $293000.0 in 2021, then jumped by 481.23% to $1.7 million in 2022, then retreated by 27.54% to $1.2 million in 2023, then slumped by 75.12% to $307000.0 in 2024.
• The last three Capital Leases figures came in at $307000.0 (Q3 2024), $953000.0 (Q2 2024), and $1.1 million (Q1 2024), per Business Quant data.